Treatment with the aldosterone synthase inhibitor lorundrostat significantly decreased automated office systolic blood pressure in adults with uncontrolled hypertension in the phase 2 TARGET-HTN trial.
Medscape Medical News
‘New Dawn’ for Aldosterone as Drug Target in Hypertension?
